Artiva Biotherapeutics, Inc. Announces 2026 Annual Meeting Date & Shareholder Proposal Deadlines
Key Points from the SEC Filing
- Annual Meeting Date Set: Artiva Biotherapeutics, Inc. (“Artiva” or “the Company”) has announced that its 2026 annual meeting of stockholders (“Annual Meeting”) will be held on September 8, 2026.
- Unusual Timing: The announced date is more than 70 days after the one-year anniversary of the Company’s 2025 annual meeting. This deviation from the typical schedule may be of interest to shareholders and could have implications for proxy planning and corporate governance activities.
- Shareholder Proposal & Director Nomination Deadlines:
- Shareholders must submit notices for any business to be brought before the Annual Meeting or for nominations to the Company’s Board of Directors by the close of business on August 1, 2026.
- Proposals intended for inclusion in the Company’s proxy statement (pursuant to Rule 14a-8 of the Securities Exchange Act of 1934) must also be received by August 1, 2026. This is considered a reasonable time before the Company begins printing and mailing proxy materials.
- All submissions must comply with the requirements in the Company’s amended and restated bylaws, SEC regulations, and other applicable laws. Notices and proposals must be addressed to: Artiva Biotherapeutics, Inc., Attention: Secretary, 5505 Morehouse Drive, Suite 100, San Diego, California 92121.
- Emerging Growth Company Status: Artiva Biotherapeutics is designated as an “emerging growth company” under SEC rules. The Company has not elected to use the extended transition period for complying with new or revised financial accounting standards.
- Security Information: The Company’s common stock (\$0.0001 par value per share) is traded under the symbol ARTV on the Nasdaq Global Market.
Important Information for Shareholders
- Shareholder Action Required: If you wish to bring forward a proposal or nominate a director at the 2026 Annual Meeting, your notice must be submitted by August 1, 2026. Late submissions will not be considered.
- Proxy Statement Inclusion: Proposals for inclusion in the proxy statement must meet all requirements under Rule 14a-8 and the Company’s bylaws. Failure to comply may result in exclusion from proxy materials.
- Potential Price Sensitivity: The timing of the Annual Meeting and the deadline for shareholder proposals could be significant for activist shareholders or those seeking changes in board composition or corporate strategy. Any unexpected nominations or proposals submitted by the deadline could affect the Company’s governance, strategic direction, and potentially its share price.
- Emerging Growth Company Implications: The Company’s status as an emerging growth company means that it may benefit from certain regulatory exemptions, which may be of interest to investors monitoring compliance and reporting standards.
Potential Impacts on Share Price
- The unusual timing of the Annual Meeting, being held over 70 days after the prior year’s anniversary, may indicate internal planning or governance changes. This could attract attention from institutional investors or activist shareholders.
- New shareholder proposals or director nominations submitted by August 1, 2026, could result in changes to board composition or influence corporate strategy. Any such proposals, if material, could impact investor sentiment and share price.
- The Company’s continued designation as an emerging growth company may affect its financial reporting practices and regulatory compliance costs, which could be relevant for valuation and risk assessment.
Additional Details
- Company Address: 5505 Morehouse Drive, Suite 100, San Diego, California 92121.
- SEC CIK: 0001817241
- Fiscal Year End: December 31
- Commission File Number: 001-42179
- Business Phone: (858) 267-4467
Disclaimer
This article is based on information contained in Artiva Biotherapeutics, Inc.’s SEC Form 8-K dated July 22, 2026. The content herein is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any securities. Investors should conduct their own due diligence and consult with professional advisors prior to making investment decisions. The information provided is accurate as of the date of publication and may be subject to change.
